

ZFP36 ring finger protein like 1 significantly suppresses human coronavirus OC43 replication

Tooba Momin¹, Andrew Villasenor¹, Amit Singh¹, Mahmoud Darweesh², Mrigendra Rajput^{Corresp. 1}

¹ Department of Biology, University of Dayton, Dayton, Ohio, United States

² Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Uppsala, Sweden

Corresponding Author: Mrigendra Rajput
Email address: mrajput1@udayton.edu

CCCH-type Zinc finger proteins (ZFP) are small cellular proteins that are structurally maintained by zinc ions. Zinc ions coordinate the protein structure in a tetrahedral geometry by binding cysteines or cysteines and histidine amino acids. The unique structure of ZFP enables it to interact with a wide variety of molecules including RNA and thus modulate several cellular processes including host immune response and virus replication. CCCH-type ZFPs have shown their antiviral efficacy against several DNA and RNA viruses. However, their role in human coronavirus still needs to be characterized. The current study evaluated the effect of ZFP36L1, a CCCH-type ZFP on human coronavirus (HCoV)-OC43. We overexpressed or knockdown the ZFP36L1 in HCT-8 cells using lentivirus transduction. Wild type, ZFP36L1 overexpressed, or ZFP36L1 knockdown cells were infected with HCoV-OC43 and virus titer in these cells was measured over 96 hours post-infection (p.i.). Results of the current study showed that HCoV-OC43 replication was significantly reduced with overexpression of ZFP36L1 while knockdown of ZFP36L1 significantly enhanced the virus replication. ZFP36L1 knockdown HCT-8 cells started producing the infectious HCoV-OC43 at 48 hours post-infection which was much earlier as compared to wild-type or ZFP36L1 overexpressed HCT-8 cells which started producing infectious virus at 72 hours post-infection. Overall, the current study showed that overexpression of ZFP36L1 suppressed human coronavirus (OC43) production.

1 ZFP36 Ring Finger Protein Like 1 significantly suppresses
2 Human coronavirus OC43 replication

3

4 Tooba Momin¹, Andrew Villasenor¹, Amit Singh¹, Mahmoud Darweesh², Mrigendra Rajput¹

5

6

7 ¹Department of Biology, University of Dayton, Dayton, Ohio, USA 45469

8 ²Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden,

9 75105

10

11

12 Corresponding Author:

13 Mrigendra Rajput

14 SC 234, Department of Biology, 300 College Street, University of Dayton, Dayton, Ohio, 45469,

15 USA

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38 Abstract

39 CCCH-type Zinc finger proteins (ZFP) are small cellular proteins that are structurally maintained
40 by zinc ions. Zinc ions coordinate the protein structure in a tetrahedral geometry by binding
41 cysteines or cysteines and histidine amino acids. The unique structure of ZFP enables it to
42 interact with a wide variety of molecules including RNA and thus modulate several cellular
43 processes including host immune response and virus replication. CCCH-type ZFPs have shown
44 their antiviral efficacy against several DNA and RNA viruses. However, their role in human
45 coronavirus still needs to be characterized.

46 The current study evaluated the effect of ZFP36L1, a CCCH-type ZFP on human coronavirus
47 (HCoV)-OC43. We overexpressed or knockdown the ZFP36L1 in HCT-8 cells using lentivirus
48 transduction. Wild type, ZFP36L1 overexpressed, or ZFP36L1 knockdown cells were infected
49 with HCoV-OC43 and virus titer in these cells was measured over 96 hours post-infection (p.i.).
50 Results of the current study showed that HCoV-OC43 replication was significantly reduced with
51 overexpression of ZFP36L1 while knockdown of ZFP36L1 significantly enhanced the virus
52 replication. ZFP36L1 knockdown HCT-8 cells started producing the infectious HCoV-OC43 at
53 48 hours post-infection which was much earlier as compared to wild-type or ZFP36L1
54 overexpressed HCT-8 cells which started producing infectious virus at 72 hours post-infection.
55 Overall, the current study showed that overexpression of ZFP36L1 suppressed human
56 coronavirus (OC43) production.

57

58

59

60

61

62

63 Keywords: CCCH type Zinc finger protein, ZFP36L1, RNA binding protein, human coronavirus
64 OC43

65 **Introduction**

66 ZFPs are small cellular proteins that are structurally maintained by zinc ions. Zinc ions coordinate
67 the protein structure in a tetrahedral geometry [1, 2]. There are more than 40 different types of ZFP
68 that have been annotated so far [2]. The unique structure of ZFP enables it to interact with a wide
69 variety of molecules such as DNA, RNA, PAR (poly-ADP-ribose), and cellular proteins and thus
70 modulate several cellular processes including host immune response and virus replication [3-11].
71 Among various ZFPs, one family known as CCCH-type ZFP where Zinc ions coordinate the
72 protein structure by binding cysteines or cysteines and histidine amino acids[1, 2], has been
73 characterized for its antiviral [2, 10, 12-21] and immune modulator activity [22-35].

74 A few of the known mechanisms by which CCCH-type ZFPs exhibit these antiviral or
75 immunomodulatory activities are, that they limit the total mRNA turnover in the cell. CCCH type
76 ZFPs have two tandem zinc finger (TZF) domains that bind to adenyl and uracyl nucleotides rich
77 (AU-rich) elements (AREs) in mRNA and lead to the removal of the poly(A) tail from the mRNA
78 by promoting its deadenylation and degradation [36-41]. CCCH-type ZFPs also have the ability to
79 interact with cellular mRNA decaying enzymes such as exoribonuclease (5' -3' exoribonuclease
80 XRN1 and 3' -5' exoribonuclease exosome complex) or decapping enzymes (DCP1 and DCP2),
81 and these interactions promote the degradation of mRNA[41]. CCCH-type ZFPs also exhibit their
82 antiviral and immunomodulatory activity by inhibiting the translation process. CCCH-type ZFPs
83 disrupt the interaction between eIF4G and eIF4A, preventing protein translation and leading to
84 RNA degradation [42]. As an eIF4G- eIF4F complex is needed for recruiting the 40S ribosomal
85 subunit for translation [43].

86 CCCH-type ZFPs showed their antiviral efficacy against several RNA viruses including Influenza
87 A virus [10], retrovirus[15, 44, 45], filoviruses [8], and alphavirus such as Sindbis virus, Semliki
88 Forest virus, Ross River virus, and Venezuelan equine encephalitis virus [46]. However, the role

89 of CCCH-type ZFPs on the human coronavirus is little explored. To fill that knowledge gap current
90 study evaluated the effect of ZFP36L1, a CCCH-type ZFP on human coronavirus (HCoV)-OC43.

91

92 **Materials & Methods**

93

94 **Cells, Virus Strains and Virus Propagation**

95 The current study used human coronavirus (HCoV)-OC43 (ATCC catalog number VR1558)
96 which was purchased from American Type Culture Collection (ATCC, Manassas, VA). Virus
97 stock was prepared in HCT-8 cells (ATCC catalog number CCL-244, ATCC, Manassas, VA).
98 HCT-8 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium (Gibco
99 BRL, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS), and
100 antibiotic-antimycotic (penicillin 100 units /ml, streptomycin 0.10 mg /ml and amphotericin B
101 0.25 µg /ml) (Sigma-Aldrich, St. Louis, MO). During virus culture, HCT-8 cells were adopted to
102 1% FBS. HCT-8 cells culture with RPMI 1640 medium supplemented with 1% FBS were used
103 to grow the virus and for virus titration.

104 **Overexpression and knockdown of ZFP36L1**

105 HCT-8 cells were stably overexpressed for ZFP36L1 (NCBI reference sequence:
106 NM_001244701.1) with green fluorescent protein (GFP) marker using lentivirus. The
107 overexpressed sequence for ZFP36L1 contained both tandem zinc finger domains (TZFD) such as
108 TZFD1 and TZFD2. While HCT-8 cells were knockdown for ZFP36L1 using lentivirus with
109 “GTAACAAGATGCTCAACTATA” as a target sequence for ZFP36L1 with upstream mCherry
110 marker. Successful transduction was measured through GFP or mCherry expression for
111 ZFP36L1 overexpression and ZFP36L1 knockdown, respectively. Transduced HCT-8 cells were
112 selected with increased concentration of puromycin (2-3 µg/ml) over 7 days.

113 Western blot analysis for ZFP36L1 overexpression and knockdown confirmation

114 ZFP36L1 overexpression or knockdown was confirmed by western blot. Wild type, ZFP36L1
115 overexpressed or ZFP36L1 knockdown HCT-8 cells were seeded in T25 flask. When cells reach
116 75-80% confluency then cells were lysed using radioimmunoprecipitation assay buffer (RIPA
117 buffer) (Cell Signaling Technology, Danvers, MA) supplemented with Protease-Phosphatase
118 Inhibitor (Cell Signaling Technology, Danvers, MA). Lysate were centrifuged at 3000 X g for 15
119 minutes at 4 °C. Supernatant was collected and protein concentration in each supernatant was
120 measured using Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA). A
121 40 µg cell lysate were run through 12% resolving SDS PAGE gel, after running, protein were
122 transfected to polyvinylidene difluoride (PVDF) membrane (Thermo Fisher Scientific, Waltham,
123 MA). Membrane was blocked with 5% skimmed milk (Sigma-Aldrich, St. Louis, MO) in Tris-
124 buffered saline (TBS) for 1 h at room temperature followed by incubation with anti- ZFP36L1
125 antibody (1:1000) (Thermo Fisher Scientific, Waltham, MA) and anti- β actin antibody (1:4000)
126 (Cell Signaling Technology, Danvers, MA) overnight at 4 °C. Membranes were washed with
127 Tris-Buffered Saline +0.1% Tween 20 (TBST) and incubated with HRP conjugated secondary
128 antibodies (1:2000). Membrane was developed using Pierce ECL Western Blotting Substrate
129 (Thermo Fisher Scientific, Waltham, MA). Image of western blot was taken by Odyssey XF
130 Imaging System (LI-COR Biosciences, Lincoln, NE).

131 Measuring the effect of ZFP36L1 expression on virus titration

132 Wild type, ZFP36L1 overexpressed or ZFP36L1 knockdown HCT-8 cells were infected with
133 HCoV-OC43 with 0.1 multiple of infection (MOI). Supernatant from these cells were collected
134 at 24 hours, 48 hours, 72 hours and 96 hours post infection (p.i.). Collected cell supernatants
135 were centrifuged at 1000Xg at 4°C for 15 minutes to remove cell debris and stored at -80 ° C till

136 used. Once samples from all time point were collected, virus titer in those samples were estimate
137 for HCoV-OC43 virus titer as per the method described earlier [47].

138 **Statistical analysis**

139 The significant change in HCoV-OC43 titer in wild-type, ZFP36L1 overexpression, or ZFP36L1
140 knockdown cells was estimated using paired T-test with a 95% degree of freedom. Virus titer in
141 wild-type, ZFP36L1 overexpression or ZFP36L1 knockdown cells were repeated at least three
142 times, and average, standard deviation, and error were calculated.

143

144 **Results**

145

146 **ZFP36L1 was successfully overexpressed and knockdown in HCT-8 cells.**

147 A stable ZFP36L1 overexpression with GFP marker in HCT-8 cells was performed using a
148 lentivirus system. GFP expression in HCT-8 cells was considered for ZFP36L1 overexpression
149 (Figure 1B), which was further confirmed by western blot (Figure 2). Similarly, ZFP36L1
150 knockdown where shRNA was located downstream to mCherry was confirmed by mCherry
151 expression (Figure 1C) as well as western blot analysis (Figure 2).

152

153 **ZFP36L1 overexpression significantly suppressed the human coronavirus (HCoV)-OC43**

154 **virus production**

155 Wild type and ZFP36L1 overexpressed HCT-8 cells were infected with HCoV-OC43 with
156 M.O.I. of 0.1. Cell supernatants were collected at 24 hours, 48 hours, 72 hours, and 96 hours p.i.
157 and analyzed for virus titer.

158 Results showed that ZFP36L1 overexpression in HCT-8 cells significantly reduced virus titer
159 ($p < 0.05$) (Figure 3). Virus titer in ZFP36L1 overexpression were $2.24 \pm 1.28 \log_{10}/\text{ml}$ and

160 4.32±0.00 log₁₀/ml at 72 hours and 96 hours p.i. respectively. Which was significantly lower
161 than virus titer in wild-type cells at the same time points such as 72 hours p.i. (4.08±0.11 log
162 10/ml) or 96 hours p.i. (5.42±0.10 log 10/ml) (p<0.05) (Figure 3).

163 **3.3 ZFP36L1 knockdown significantly enhanced the human coronavirus (HCoV)-OC43** 164 **virus production as compared to control cells**

165 Results with ZFP36L1 knockdown HCT-8 cells showed that ZFP36L1 knockdown significantly
166 enhanced virus titer (p<0.05) (Figure 3). Knocking down ZFP36L1 also facilitated the infectious
167 virus production as early as 48 hours post-infection (p.i.) while wild-type cells produced
168 infectious virus at 72 hours p.i. Virus titer in ZFP36L1 knockdown cells was recorded as
169 0.00±0.00 log 10/ml, 2.86±0.00 log 10/ml, 4.52±0.22 log 10/ml, and 5.85±0.01 log 10/ml at 24
170 hours, 48 hours, 72 hours and 96 hours p.i. respectively while wild-type HCT-8 cells have virus
171 titer of 0.00±0.00 log 10/ml, 0.00±0.00 log 10/ml, 4.08±0.11 log 10/ml, and 5.42±0.10 log 10/ml
172 at 24 hours, 48 hours, 72 hours and 96 hours p.i. respectively. Virus titer in ZFP36L1
173 knockdown cells was significantly higher at 48 hours pi. and 96 hours p.i as compared to wild-
174 type cells (p<0.05) (Figure 3).

175

176 **Discussion**

177 The current study was designed to determine the role of ZFP36L1 (a CCCH type ZFP) on

178 HCoV-OC43 replication. Our results showed that overexpression of ZFP36L1 significantly

179 reduced infectious HCoV-OC43 production while ZFP36L1 knockdown significantly enhanced

180 virus titer as compared to wild-type cells.

181 ZFPS are one of the most abundant proteins in humans which can make up to 5% of total human

182 proteins[48]. ZFPs have an extremely high binding ability. It can bind to cellular DNA, RNA,

183 lipids, proteins, and PAR (poly-ADP-ribose), and therefore can modulate several cellular types of

184 machinery [3-11, 48]. The diverse binding properties of ZFPs make it difficult to characterize their
185 functional effect in the cells [48]. However, such a challenge is overcome by classifying the ZFP
186 and then identifying their functional characteristics [49]. Classification of ZFP is based on zinc
187 ion, zinc ion interaction with specific amino acids, and folded structure of the protein [50]. Based
188 on such classification CCCH type ZFP is characterized to interact with RNA and thus modulate
189 RNA metabolism in the cell [51] including interfering with RNA virus replication [15, 52].
190 CCCH type ZFPs including ZFP36L1 have two tandem zinc finger (TZF) domains that interact
191 with AU-rich elements (AREs) of poly (A) tail of mRNA, leading to its removal and thus
192 promoting mRNA degradation [36-41]. The coronavirus genome is 5'-capped with a 3' poly(A)
193 tail of variable length [53]. The length of the poly (A) tail varies at different stages of the virus
194 replication cycle and the virus with longer poly (A) tail replicates at a faster rate [54]. Therefore,
195 the effect of ZFP36L1 on viral poly (A) may be the reason for reduced virus production with
196 ZFP36L1 overexpression in the current study.
197 However, there is the possibility that ZFP can affect viral RNA replication with different
198 mechanisms. A study showed that CCCH Type ZFP also targets the non-ARE sequence of 3' and
199 5' (untranslated region) UTR of mRNA [55]. While another study showed that CCCH Type ZFP
200 targets CG-rich viral sequences [5]. The study also showed that ZFP36 (ZFP36L1) suppressed the
201 virus production (influenza A virus) by interfering with viral protein translation/ export from the
202 nucleus to the cytoplasm without affecting viral RNA replication [56]. Therefore, a detailed study
203 to determine the mechanism of action for ZFP36L1 in suppressing coronavirus replication needs
204 to be explored.

205

206 **Conclusions**

207 The current study showed that overexpression of ZFP36L1, a CCCH type ZFP significantly
208 reduced that HCoV-OC43 production. While ZFP36L1 knockdown significantly enhanced the
209 HCoV-OC43 production. However, the mechanism of such virus reduction is still needs to be
210 explored.

211

212 Acknowledgments

213 The author thanks the Department of Biology, University of Dayton, Ohio, USA, for providing
214 support to conduct the current research.

215

216 References

- 217 1. Abbehausen, C., *Zinc finger domains as therapeutic targets for metal-based compounds -*
218 *an update*. Metallomics, 2019. **11**(1): p. 15-28.
- 219 2. Hajikhezri, Z., et al., *Role of CCCH-Type Zinc Finger Proteins in Human Adenovirus*
220 *Infections*. Viruses, 2020. **12**(11).
- 221 3. Cassandri, M., et al., *Zinc-finger proteins in health and disease*. Cell Death Discovery,
222 2017. **3**(1): p. 17071.
- 223 4. Wang, G. and C. Zheng, *Zinc finger proteins in the host-virus interplay: multifaceted*
224 *functions based on their nucleic acid-binding property*. FEMS Microbiol Rev, 2021. **45**(3).
- 225 5. Meagher, J.L., et al., *Structure of the zinc-finger antiviral protein in complex with RNA*
226 *reveals a mechanism for selective targeting of CG-rich viral sequences*. Proceedings of the
227 National Academy of Sciences, 2019. **116**(48): p. 24303-24309.
- 228 6. Gonzalez-Perez, A.C., et al., *The Zinc Finger Antiviral Protein ZAP Restricts Human*
229 *Cytomegalovirus and Selectively Binds and Destabilizes Viral UL4/UL5 Transcripts*.
230 mBio, 2021. **12**(3).
- 231 7. Syed Lal, B., A. Ullah, and S. Syed, *The Role of Zinc-Finger Antiviral Proteins in Immunity*
232 *against Viruses*. Molecular Genetics, Microbiology and Virology, 2020. **35**(2): p. 78-84.
- 233 8. Müller, S., et al., *Inhibition of filovirus replication by the zinc finger antiviral protein*.
234 Journal of virology, 2007. **81**(5): p. 2391-2400.
- 235 9. Takata, M.A., et al., *CG dinucleotide suppression enables antiviral defence targeting non-*
236 *self RNA*. Nature, 2017. **550**(7674): p. 124-127.
- 237 10. Tang, Q., X. Wang, and G. Gao, *The Short Form of the Zinc Finger Antiviral Protein*
238 *Inhibits Influenza A Virus Protein Expression and Is Antagonized by the Virus-Encoded*
239 *NSI*. Journal of virology, 2017. **91**(2): p. e01909-16.
- 240 11. Nchioua, R., et al., *SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite*
241 *Preadaptation to the Low-CpG Environment in Humans*. mBio, 2020. **11**(5).
- 242 12. Zhang, B., et al., *Zinc Finger CCCH-Type Antiviral Protein 1 Restricts the Viral*
243 *Replication by Positively Regulating Type I Interferon Response*. Frontiers in
244 microbiology, 2020. **11**: p. 1912-1912.

- 245 13. Guo, X., et al., *The zinc finger antiviral protein directly binds to specific viral mRNAs*
246 *through the CCCH zinc finger motifs.* J Virol, 2004. **78**(23): p. 12781-7.
- 247 14. Zhao, Y., et al., *ZAP, a CCCH-Type Zinc Finger Protein, Inhibits Porcine Reproductive*
248 *and Respiratory Syndrome Virus Replication and Interacts with Viral Nsp9.* J Virol, 2019.
249 **93**(10).
- 250 15. Gao, G., X. Guo, and S.P. Goff, *Inhibition of retroviral RNA production by ZAP, a CCCH-*
251 *type zinc finger protein.* Science, 2002. **297**(5587): p. 1703-6.
- 252 16. Zhu, M., et al., *CCCH-type zinc finger antiviral protein mediates antiviral immune*
253 *response by activating T cells.* J Leukoc Biol, 2020. **107**(2): p. 299-307.
- 254 17. Musah, R.A., *The HIV-1 nucleocapsid zinc finger protein as a target of antiretroviral*
255 *therapy.* Curr Top Med Chem, 2004. **4**(15): p. 1605-22.
- 256 18. Chen, S.C., K.S. Jeng, and M.M.C. Lai, *Zinc Finger-Containing Cellular Transcription*
257 *Corepressor ZBTB25 Promotes Influenza Virus RNA Transcription and Is a Target for*
258 *Zinc Ejector Drugs.* J Virol, 2017. **91**(20).
- 259 19. Scozzafava, A., et al., *Anticancer and antiviral sulfonamides.* Curr Med Chem, 2003.
260 **10**(11): p. 925-53.
- 261 20. Schito, M.L., et al., *Preclinical evaluation of a zinc finger inhibitor targeting lentivirus*
262 *nucleocapsid protein in SIV-infected monkeys.* Curr HIV Res, 2006. **4**(3): p. 379-86.
- 263 21. Planel, S., et al., *A novel concept in antiangiogenic and antitumoral therapy: multitarget*
264 *destabilization of short-lived mRNAs by the zinc finger protein ZFP36L1.* Oncogene, 2010.
265 **29**(45): p. 5989-6003.
- 266 22. Angiolilli, C., et al., *ZFP36 family members regulate the pro-inflammatory features of*
267 *psoriatic dermal fibroblasts.* Journal of Investigative Dermatology, 2021.
- 268 23. Wang, K.-T., et al., *Functional regulation of Zfp36l1 and Zfp36l2 in response to*
269 *lipopolysaccharide in mouse RAW264.7 macrophages.* Journal of Inflammation, 2015.
270 **12**(1): p. 42.
- 271 24. Tu, Y., et al., *Tristetraprolin specifically regulates the expression and alternative splicing*
272 *of immune response genes in HeLa cells.* BMC Immunology, 2019. **20**(1): p. 13.
- 273 25. Haneklaus, M., et al., *The RNA-binding protein Tristetraprolin (TTP) is a critical negative*
274 *regulator of the NLRP3 inflammasome.* The Journal of biological chemistry, 2017.
275 **292**(17): p. 6869-6881.
- 276 26. Lv, L., et al., *Targeting Tristetraprolin Expression or Functional Activity Regulates*
277 *Inflammatory Response Induced by MSU Crystals.* Frontiers in immunology, 2021. **12**: p.
278 675534-675534.
- 279 27. Matsushita, K., et al., *Zc3h12a is an RNase essential for controlling immune responses by*
280 *regulating mRNA decay.* Nature, 2009. **458**(7242): p. 1185-90.
- 281 28. Wawro, M., J. Kochan, and A. Kasza, *The perplexities of the ZC3H12A self-mRNA*
282 *regulation.* Acta Biochim Pol, 2016. **63**(3): p. 411-5.
- 283 29. Uehata, T. and S. Akira, *mRNA degradation by the endoribonuclease Regnase-*
284 *1/ZC3H12a/MCPIP-1.* Biochim Biophys Acta, 2013. **1829**(6-7): p. 708-13.
- 285 30. Chen, X.F., et al., *Role of Zc3h12a in enhanced IL-6 production by newborn mononuclear*
286 *cells in response to lipopolysaccharide.* Pediatr Neonatol, 2018. **59**(3): p. 288-295.
- 287 31. Mino, T., et al., *Regnase-1 and Roquin Regulate a Common Element in Inflammatory*
288 *mRNAs by Spatiotemporally Distinct Mechanisms.* Cell, 2015. **161**(5): p. 1058-1073.
- 289 32. Fu, M. and P.J. Blackshear, *RNA-binding proteins in immune regulation: a focus on CCCH*
290 *zinc finger proteins.* Nature Reviews Immunology, 2017. **17**(2): p. 130-143.

- 291 33. Stumpo, D.J., W.S. Lai, and P.J. Blakeshear, *Inflammation: cytokines and RNA-based*
292 *regulation*. Wiley Interdiscip Rev RNA, 2010. **1**(1): p. 60-80.
- 293 34. Shrestha, A., N.T. Pun, and P.-H. Park, *ZFP36L1 and AUF1 Induction Contribute to the*
294 *Suppression of Inflammatory Mediators Expression by Globular Adiponectin via*
295 *Autophagy Induction in Macrophages*. Biomolecules & therapeutics, 2018. **26**(5): p. 446-
296 457.
- 297 35. Kontoyiannis, D.L., *An RNA checkpoint that keeps immunological memory at bay*. Nature
298 Immunology, 2018. **19**(8): p. 795-797.
- 299 36. Lai, W.S., et al., *Interactions of CCCH zinc finger proteins with mRNA. Binding of*
300 *tristetraprolin-related zinc finger proteins to Au-rich elements and destabilization of*
301 *mRNA*. J Biol Chem, 2000. **275**(23): p. 17827-37.
- 302 37. Lai, W.S., et al., *Importance of the Conserved Carboxyl-Terminal CNOT1 Binding Domain*
303 *to Tristetraprolin Activity In Vivo*. Molecular and cellular biology, 2019. **39**(13): p.
304 e00029-19.
- 305 38. Suk, F.-M., et al., *ZFP36L1 and ZFP36L2 inhibit cell proliferation in a cyclin D-dependent*
306 *and p53-independent manner*. Scientific Reports, 2018. **8**(1): p. 2742.
- 307 39. Blakeshear, P.J., *Tristetraprolin and other CCCH tandem zinc-finger proteins in the*
308 *regulation of mRNA turnover*. Biochem Soc Trans, 2002. **30**(Pt 6): p. 945-52.
- 309 40. Lai, W.S., E.A. Kennington, and P.J. Blakeshear, *Tristetraprolin and its family members*
310 *can promote the cell-free deadenylation of AU-rich element-containing mRNAs by poly(A)*
311 *ribonuclease*. Mol Cell Biol, 2003. **23**(11): p. 3798-812.
- 312 41. Lykke-Andersen, J. and E. Wagner, *Recruitment and activation of mRNA decay enzymes*
313 *by two ARE-mediated decay activation domains in the proteins TTP and BRF-1*. Genes
314 Dev, 2005. **19**(3): p. 351-61.
- 315 42. Zhu, Y., et al., *Translational repression precedes and is required for ZAP-mediated mRNA*
316 *decay*. The EMBO journal, 2012. **31**(21): p. 4236-4246.
- 317 43. Villa, N., et al., *Human eukaryotic initiation factor 4G (eIF4G) protein binds to eIF3c, -d,*
318 *and -e to promote mRNA recruitment to the ribosome*. J Biol Chem, 2013. **288**(46): p.
319 32932-40.
- 320 44. Zhu, M., et al., *Inhibition of avian tumor virus replication by CCCH-type zinc finger*
321 *antiviral protein*. Oncotarget, 2017. **8**(35): p. 58865-58871.
- 322 45. Zhu, Y., et al., *Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting*
323 *multiply spliced viral mRNAs for degradation*. Proc Natl Acad Sci U S A, 2011. **108**(38):
324 p. 15834-9.
- 325 46. Bick, M.J., et al., *Expression of the zinc-finger antiviral protein inhibits alphavirus*
326 *replication*. Journal of virology, 2003. **77**(21): p. 11555-11562.
- 327 47. REED, L.J. and H. MUENCH, *A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT*
328 *ENDPOINTS*. American Journal of Epidemiology, 1938. **27**(3): p. 493-497.
- 329 48. Vilas, C.K., et al., *Caught with One's Zinc Fingers in the Genome Integrity Cookie Jar*.
330 Trends Genet, 2018. **34**(4): p. 313-325.
- 331 49. Cassandri, M., et al., *Zinc-finger proteins in health and disease*. Cell Death Discov, 2017.
332 **3**: p. 17071.
- 333 50. Krishna, S.S., I. Majumdar, and N.V. Grishin, *Structural classification of zinc fingers:*
334 *survey and summary*. Nucleic Acids Res, 2003. **31**(2): p. 532-50.
- 335 51. Maeda, K. and S. Akira, *Regulation of mRNA stability by CCCH-type zinc-finger proteins*
336 *in immune cells*. Int Immunol, 2017. **29**(4): p. 149-155.

- 337 52. Kozaki, T., et al., *Role of zinc-finger anti-viral protein in host defense against Sindbis*
338 *virus*. Int Immunol, 2015. **27**(7): p. 357-64.
- 339 53. Fehr, A.R. and S. Perlman, *Coronaviruses: an overview of their replication and*
340 *pathogenesis*. Methods Mol Biol, 2015. **1282**: p. 1-23.
- 341 54. Wu, H.Y., et al., *Regulation of coronaviral poly(A) tail length during infection*. PLoS One,
342 2013. **8**(7): p. e70548.
- 343 55. Li, M., et al., *Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and*
344 *protects against viral myocarditis*. Antiviral Res, 2015. **123**: p. 50-61.
- 345 56. Lin, R.-J., et al., *Zinc finger protein ZFP36L1 inhibits influenza A virus through*
346 *translational repression by targeting HA, M and NS RNA transcripts*. Nucleic acids
347 research, 2020. **48**(13): p. 7371-7384.

Figure 1

Overexpression and knockdown of ZFP36L1 in HCT-8 cells

Wild type HCT8 wells (A), ZFP36L1 overexpressed HCT-8 cells with GFP marker (B), and ZFP36L1 knockdown HCT-8 cells with mCherry marker (C). Overexpression and knockdown of ZFP36L1 were performed by lentivirus transduction.




Figure 2

Western blot for confirming ZFP36L1 overexpression and knockdown in HCT-8 cells

Cell lysate for ZFP36L1 knockdown (A), ZFP36L1 overexpressed (B) and wild-type HCT-8 cells were separated with 12% resolving SDS PAGE gel and transferred to PVDF membrane. Proteins on the membrane were detected with anti-ZFP36L1 antibody and anti- β actin antibody with HRP-conjugated secondary antibodies




Figure 3

Human coronavirus-OC43 titer in HCT-8 cells

Wild type, ZFP36L1 overexpressed or ZFP36L1 knockdown HCT-8 cells were infected with HCoV-OC43 with 0.1 MOI. Supernatant from these cells was collected at 24 hours, 48 hours, 72 hours, and 96 hours p.i. and analyzed for virus titer. Asterisks are showing significant differences in virus titer

